These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 14675014)

  • 1. Implantable cardioverter defibrillator events in patients with asymptomatic nonsustained ventricular tachycardia: is device implantation justified?
    Russo AM; Nayak H; Verdino R; Springman J; Gerstenfeld E; Hsia H; Marchlinski FE
    Pacing Clin Electrophysiol; 2003 Dec; 26(12):2289-95. PubMed ID: 14675014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
    Roses-Noguer F; Jarman JW; Clague JR; Till J
    Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial.
    Klein RC; Raitt MH; Wilkoff BL; Beckman KJ; Coromilas J; Wyse DG; Friedman PL; Martins JB; Epstein AE; Hallstrom AP; Ledingham RB; Belco KM; Greene HL;
    J Cardiovasc Electrophysiol; 2003 Sep; 14(9):940-8. PubMed ID: 12950538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
    Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
    J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High incidence of appropriate and inappropriate ICD therapies in children and adolescents with implantable cardioverter defibrillator.
    Korte T; Köditz H; Niehaus M; Paul T; Tebbenjohanns J
    Pacing Clin Electrophysiol; 2004 Jul; 27(7):924-32. PubMed ID: 15271011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure of third-generation implantable cardioverter defibrillators to abort shock therapy for nonsustained ventricular tachycardia due to shortcomings of the VF confirmation algorithm.
    Grimm W; Menz V; Hoffmann J; Maisch B
    Pacing Clin Electrophysiol; 1998 Apr; 21(4 Pt 1):722-7. PubMed ID: 9584303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival After Implantable Cardioverter-Defibrillator Shocks.
    Aktaş MK; Younis A; Zareba W; Kutyifa V; Klein H; Daubert JP; Estes M; McNitt S; Polonsky B; Goldenberg I
    J Am Coll Cardiol; 2021 May; 77(20):2453-2462. PubMed ID: 34016257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial.
    Sweeney MO; Wathen MS; Volosin K; Abdalla I; DeGroot PJ; Otterness MF; Stark AJ
    Circulation; 2005 Jun; 111(22):2898-905. PubMed ID: 15927965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programming implantable cardioverter-defibrillator therapy zones to high ranges to prevent delivery of inappropriate device therapies in patients with primary prevention: results from the RISSY-ICD (Reduction of Inappropriate ShockS bY InCreaseD zones) trial.
    Cay S; Canpolat U; Ucar F; Ozeke O; Ozcan F; Topaloglu S; Aras D
    Am J Cardiol; 2015 May; 115(9):1235-43. PubMed ID: 25765588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term outcome after cardioverter-defibrillator implantation in patients with Brugada syndrome].
    Binbin Y; Jingping L; Bing Y; Minglong C; Jiangang Z; Kejiang C; Qijun S
    Zhonghua Xin Xue Guan Bing Za Zhi; 2015 Aug; 43(8):690-4. PubMed ID: 26955725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reassessing the role of antitachycardia pacing in fast ventricular arrhythmias in primary prevention implantable cardioverter-defibrillator recipients: Results from MADIT-RIT.
    Schuger C; Daubert JP; Zareba W; Rosero S; Yong P; McNitt S; Kutyifa V
    Heart Rhythm; 2021 Mar; 18(3):399-403. PubMed ID: 33232811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitachycardia pacing reduces appropriate and inappropriate shocks in children and congenital heart disease patients.
    Kalra Y; Radbill AE; Johns JA; Fish FA; Kannankeril PJ
    Heart Rhythm; 2012 Nov; 9(11):1829-34. PubMed ID: 22766560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT).
    Ruwald AC; Schuger C; Moss AJ; Kutyifa V; Olshansky B; Greenberg H; Cannom DS; Estes NA; Ruwald MH; Huang DT; Klein H; McNitt S; Beck CA; Goldstein R; Brown MW; Kautzner J; Shoda M; Wilber D; Zareba W; Daubert JP
    Circ Arrhythm Electrophysiol; 2014 Oct; 7(5):785-92. PubMed ID: 25136077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
    JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reprogramming the tachycardia parameters with long-detection strategy in patients with pre-existing implantable cardioverter-defibrillator.
    Bozyel S; Aktas M; Mutluer FO; Guler TE; Dervis E; Argan O; Celikyurt U; Agir A; Vural A
    Acta Cardiol; 2019 Jun; 74(3):246-251. PubMed ID: 30058473
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term clinical outcome in patients with severe left ventricular dysfunction and an implantable cardioverter-defibrillator after ventricular tachyarrhythmias.
    Pelicano N; Oliveira M; Da Silva N; Antunes E; Santos S; Conceição JM; Roquette J; Quininha J
    Rev Port Cardiol; 2005 Apr; 24(4):487-98. PubMed ID: 15977773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study.
    Powell BD; Saxon LA; Boehmer JP; Day JD; Gilliam FR; Heidenreich PA; Jones PW; Rousseau MJ; Hayes DL
    J Am Coll Cardiol; 2013 Oct; 62(18):1674-1679. PubMed ID: 23810882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders.
    Anselme F; Moubarak G; Savouré A; Godin B; Borz B; Drouin-Garraud V; Gay A
    Heart Rhythm; 2013 Oct; 10(10):1492-8. PubMed ID: 23811080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Supraventricular arrhythmias in children and young adults with implantable cardioverter defibrillators.
    Love BA; Barrett KS; Alexander ME; Bevilacqua LM; Epstein MR; Triedman JK; Walsh EP; Berul CI
    J Cardiovasc Electrophysiol; 2001 Oct; 12(10):1097-101. PubMed ID: 11699514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.